In July 2024, representatives from Singapore’s Health Sciences Authority (HSA) visited Ko Da Pharmaceutical’s headquarters and GMP-certified manufacturing site in Taoyuan, Taiwan.

During the visit, HSA officials gained insights into Ko Da’s approach to modernizing Chinese medicine, its robust quality control systems, and its advanced traceability mechanisms. The visit reinforced mutual understanding in regulatory cooperation and product registration processes. Ko Da’s efforts in maintaining high manufacturing standards were well recognized and appreciated.

2024年7月，新加坡衛生科學局（Health Sciences Authority, HSA）代表來訪台灣，實地參觀位於桃園的科達製藥總部與GMP製造廠，深入了解科達在中藥現代化、生產品質管理及原料追溯系統上的實踐。此次參訪進一步強化雙方在法規合作與產品註冊交流上的互信，並對科達的生產規格與管理系統給予高度肯定。

🔗 [點此閱讀完整內容 / Read More]